Anti-depressant like Effect of Pimozide in Acute and Chronic Animal Models of Depression

dc.contributor.authorMahesh, R.
dc.date.accessioned2023-11-23T06:19:33Z
dc.date.available2023-11-23T06:19:33Z
dc.date.issued2015-02
dc.description.abstractThe hope of developing better antidepressants has stimulated research on 5-HT receptor, capable of producing diverse antidepressant-like 7 behavioral effects. In the current study, the pimozide, a novel 5-HT receptor antagonist, was screened for its antidepressant potential in 7 rodent's behavioral test battery. Psycho-pharmacological investigations involved acute and chronic treatment (14 days) of pimozide in forced swim test (FST), tail suspension test (TST) in mice and olfactory bulbectomy in rats, respectively. Dose response study in mice FST and TST revealed the initial antidepressant-like effect of pimozide (0.5-4mg/kg i.p.). Interaction studies revealed that pimozide (1and 2mg/kg) significantly enhanced the antidepressant action of citalopram and bupropion in mice FST and TST respectively. Reversal of reserpine induced hypothermia (rats) was observed at same dose level. Further, the behavior anomalies exhibited by olfactory bulbectomised rats (OBX) were attenuated by chronic pimozide treatment as observed in open field and hyper-emotionality tests. In conclusion, this behavioural study depicts the antidepressant-like effect of pimozide in rodent's behavioural model.en_US
dc.identifier.urihttps://www.ijper.org/article/306
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13231
dc.language.isoenen_US
dc.publisherIJPERen_US
dc.subjectPharmacyen_US
dc.subjectAnti-depressant-like effecten_US
dc.subject5-HT3 antagonisten_US
dc.subjectPimozideen_US
dc.subjectForced swim test (FST)en_US
dc.subjectOlfactory bulbectomy (OBX)en_US
dc.titleAnti-depressant like Effect of Pimozide in Acute and Chronic Animal Models of Depressionen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: